Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation

Citations Over TimeTop 14% of 2008 papers

Abstract

A series of naphthyl-based compounds were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptors. Investigations of structure-activity relationships led to the identification of a series of naphthamides that are potent inhibitors of the VEGF receptor tyrosine kinase family. Numerous analogues demonstrated low nanomolar inhibition of VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation, and of these several compounds possessed favorable pharmacokinetic (PK) profiles. In particular, compound 48 demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice. A full account of the preparation, structure-activity relationships, pharmacokinetic properties, and pharmacology of analogues within this series is presented.

Related Papers

• → Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases(1999)24 cited
• → Tyrosine Phosphorylation in Oxidative Stress(1997)12 cited
• → VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition(2009)1 cited
• → Abstract PL04-03: Cell signaling by receptor tyrosine kinases: From basic principles to cancer therapy(2012)1 cited
• → Effect of small molecule tyrosine kinase inhibitors on PDGF-AA/BB and PDGFR-α/β-expression in HPV-positive and -negative SCC(2020)